RU2000126790A - COMPOSITION INTENDED FOR TREATMENT OF ALCOHOL AND MEDICINAL DEPENDENCE CONTAINING OPIOID ANTAGONIST AND MODULATOR OF NMDA RECEPTOR COMPLEX - Google Patents

COMPOSITION INTENDED FOR TREATMENT OF ALCOHOL AND MEDICINAL DEPENDENCE CONTAINING OPIOID ANTAGONIST AND MODULATOR OF NMDA RECEPTOR COMPLEX

Info

Publication number
RU2000126790A
RU2000126790A RU2000126790/14A RU2000126790A RU2000126790A RU 2000126790 A RU2000126790 A RU 2000126790A RU 2000126790/14 A RU2000126790/14 A RU 2000126790/14A RU 2000126790 A RU2000126790 A RU 2000126790A RU 2000126790 A RU2000126790 A RU 2000126790A
Authority
RU
Russia
Prior art keywords
modulator
opioid antagonist
nmda receptor
receptor complex
alcohol
Prior art date
Application number
RU2000126790/14A
Other languages
Russian (ru)
Other versions
RU2226107C2 (en
Inventor
Мартин ДАУСТ
Ив БОНОММ
Филипп ДЮРБЕН
Original Assignee
Лифа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98400723A external-priority patent/EP0945133A1/en
Application filed by Лифа filed Critical Лифа
Publication of RU2000126790A publication Critical patent/RU2000126790A/en
Application granted granted Critical
Publication of RU2226107C2 publication Critical patent/RU2226107C2/en

Links

Claims (10)

1. Фармацевтическая композиция для лечения алкогольной и лекарственной зависимости, включающая терапевтически эффективное количество (i) опиоидного антагониста; и (ii) модулятора NMDA рецепторного комплекса.1. A pharmaceutical composition for treating alcohol and drug dependence, comprising a therapeutically effective amount of (i) an opioid antagonist; and (ii) a modulator of the NMDA receptor complex. 2. Фармацевтическая композиция по п. 1, в которой опиоидный антагонист выбирают из налтрексона и налоксона. 2. The pharmaceutical composition according to claim 1, wherein the opioid antagonist is selected from naltrexone and naloxone. 3. Фармацевтическая композиция по п. 1, в которой опиоидный антагонист представляет собой налтрексон. 3. The pharmaceutical composition according to claim 1, wherein the opioid antagonist is naltrexone. 4. Фармацевтическая композиция по п. 1, в которой модулятор NMDA рецепторного комплекса представляет собой модулятор спермидинового сайта. 4. The pharmaceutical composition of claim 1, wherein the NMDA receptor complex modulator is a spermidine site modulator. 5. Фармацевтическая композиция по п. 4, в которой модулятор спермидинового сайта представляет собой акампросат. 5. The pharmaceutical composition according to claim 4, wherein the spermidine site modulator is acamprosate. 6. Фармацевтический набор, включающий: (i) опиоидный антагонист; и (ii) модулятор NMDA рецепторного комплекса. 6. A pharmaceutical kit comprising: (i) an opioid antagonist; and (ii) a modulator of the NMDA receptor complex. 7. Фармацевтический набор по п. 6, в котором опиоидный антагонист выбирают из налтрексона и налоксона. 7. The pharmaceutical kit according to claim 6, in which the opioid antagonist is selected from naltrexone and naloxone. 8. Фармацевтический набор по п. 6, в котором опиоидный антагонист представляет собой налтрексон. 8. The pharmaceutical kit according to claim 6, in which the opioid antagonist is a naltrexone. 9. Фармацевтический набор по п. 6, в котором модулятор NMDA рецепторного комплекса представляет собой модулятор спермидинового сайта. 9. The pharmaceutical kit according to claim 6, wherein the NMDA receptor complex modulator is a spermidine site modulator. 10. Фармацевтический набор по п. 9, в котором модулятор спермидинового сайта представляет собой акампросат. 10. The pharmaceutical kit according to claim 9, wherein the spermidine site modulator is acamprosate.
RU2000126790/15A 1998-03-26 1999-03-26 Composition indicated for treating alcoholic and medicinal addiction and containing opioid antagonist and nmda modulator of receptor complex RU2226107C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723.7 1998-03-26
EP98400723A EP0945133A1 (en) 1998-03-26 1998-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator

Publications (2)

Publication Number Publication Date
RU2000126790A true RU2000126790A (en) 2002-11-10
RU2226107C2 RU2226107C2 (en) 2004-03-27

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2000126790/15A RU2226107C2 (en) 1998-03-26 1999-03-26 Composition indicated for treating alcoholic and medicinal addiction and containing opioid antagonist and nmda modulator of receptor complex

Country Status (18)

Country Link
US (1) US6512009B1 (en)
EP (2) EP0945133A1 (en)
KR (1) KR20010034678A (en)
AT (1) ATE230993T1 (en)
AU (1) AU758569B2 (en)
BR (1) BR9909138A (en)
CA (1) CA2325739C (en)
CZ (1) CZ296367B6 (en)
DE (1) DE69904922T2 (en)
DK (1) DK1063995T3 (en)
ES (1) ES2190205T3 (en)
HK (1) HK1032542A1 (en)
HU (1) HU226555B1 (en)
NO (1) NO319313B1 (en)
PL (1) PL193241B1 (en)
RU (1) RU2226107C2 (en)
SK (1) SK284623B6 (en)
WO (1) WO1999048500A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521331A (en) * 1998-07-20 2002-07-16 ペプテック リミテッド Bioimplant formulation
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (en) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Active ingredient combination for drug addiction or intoxicant therapy
ES2187288B1 (en) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda AMINAS AS ANTI-ALCOHOLISM AGENTS.
EP1509182A4 (en) 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of buprenorphine
SI2218448T1 (en) 2002-12-13 2016-01-29 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
KR101152183B1 (en) 2003-03-31 2012-06-15 타이탄 파머슈티컬즈 인코퍼레이티드 Implantable polymeric device for sustained release of dopamine agonist
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
JP2010513569A (en) * 2006-12-19 2010-04-30 ユニバーシティ オブ バージニア パテント ファウンデーション Combined effect of topiramate and ondansetron on alcohol intake
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
ES2430940T3 (en) 2008-02-28 2013-11-22 University Of Virginia Patent Foundation Serotonin transporter gene and alcoholism treatment
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2588630A4 (en) 2010-07-02 2013-12-25 Univ Virginia Patent Found Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (en) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Implanted drug preparation of naltrexone for treating alcohol- or opioid-dependent patients
CN105120659A (en) 2013-03-15 2015-12-02 度瑞公司 Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2023023038A1 (en) * 2021-08-17 2023-02-23 Yale University Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0828489A4 (en) * 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatments using naltrexone and related compounds

Similar Documents

Publication Publication Date Title
RU2000126790A (en) COMPOSITION INTENDED FOR TREATMENT OF ALCOHOL AND MEDICINAL DEPENDENCE CONTAINING OPIOID ANTAGONIST AND MODULATOR OF NMDA RECEPTOR COMPLEX
WO1995031985A3 (en) Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
ES2729679T3 (en) Morphinan derivatives for the treatment of drug overdose
ES8505519A1 (en) Analgesic, antagonist, and/or anorectic 14-fluoromorphinans.
FI925342A0 (en) Process for the preparation of therapeutically active (+) - - (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol
HUP0101546A2 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
RU2000100756A (en) METHODS AND COMPOSITIONS FOR MODULATION OF SEXUAL HUMAN REACTION
RU2004106619A (en) COMPOSITIONS OF AN OPIOID AGONIST CONTAINING A RELEASABLE AND ISOLATED ANTAGONIST
RU2007149044A (en) SOLID DOSAGE FORMS OF DRUG DRUGS WITH IMPROVED ADMINISTRATION DURING TRANSBUCKAL ADMINISTRATION
TR200400653T4 (en) Pharmaceutical compositions.
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
DE60230632D1 (en) PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
IL149496A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
EP1275381A4 (en) Time-release coated solid compositions for oral administration
RU96119781A (en) APPLICATION OF 2-Phenyl-3-aroylbenzothiophenes to reduce the level of cholesterol in the serum, pharmaceutical composition
TR200103613T2 (en) Pharmaceutical formulations and methods containing morphine administered intranasally.
HUP0400548A3 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
HUP0401022A2 (en) Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
RU98103388A (en) (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION
BG105616A (en) Pharmaceutical compositions of analgesic effect
DE60018301D1 (en) NEW PYRIMIDINE-2,4,6-TRION DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL AGENTS CONTAINING THEM
RU97101100A (en) METHOD FOR TREATING ALCOHOLISM
CA2430281A1 (en) Use of weak opioids and mixed opioid agonists/antagonists for treatment of urinary incontinence